BRPI0513891B8 - derivados de propenil piperazina substituídos, seu uso como novos inibidores de histona deacetilase, composição farmacêutica, combinação e processo de preparação destes - Google Patents

derivados de propenil piperazina substituídos, seu uso como novos inibidores de histona deacetilase, composição farmacêutica, combinação e processo de preparação destes

Info

Publication number
BRPI0513891B8
BRPI0513891B8 BRPI0513891A BRPI0513891A BRPI0513891B8 BR PI0513891 B8 BRPI0513891 B8 BR PI0513891B8 BR PI0513891 A BRPI0513891 A BR PI0513891A BR PI0513891 A BRPI0513891 A BR PI0513891A BR PI0513891 B8 BRPI0513891 B8 BR PI0513891B8
Authority
BR
Brazil
Prior art keywords
histone deacetylase
combination
piperazine derivatives
pharmaceutical composition
preparation process
Prior art date
Application number
BRPI0513891A
Other languages
English (en)
Inventor
Arts Janine
Van Emelen Kristof
Françoise Bernadette Marconnet-Decrane Laurence
René Angibaud Patrick
Franciscus Anna Van Brandt Sven
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39294123&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0513891(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0513891A publication Critical patent/BRPI0513891A/pt
Publication of BRPI0513891B1 publication Critical patent/BRPI0513891B1/pt
Publication of BRPI0513891B8 publication Critical patent/BRPI0513891B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

derivados de propenil piperazina substituídos como novos inibidores de histona deacetilase. a presente invenção refere-se aos novos compostos de fórmula em que r¹, r², r³, r4 e x têm significados definidos, tendo atividade enzimática inibidora de histona deacetilase; sua preparação, composições contendo os mesmos e sua aplicação como um medicamento.
BRPI0513891A 2004-07-28 2005-07-25 derivados de propenil piperazina substituídos, seu uso como novos inibidores de histona deacetilase, composição farmacêutica, combinação e processo de preparação destes BRPI0513891B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP04077171.9 2004-07-28
EP04077171 2004-07-28
US59235704P 2004-07-29 2004-07-29
US60/592,357 2004-07-29
PCT/EP2005/053611 WO2006010749A2 (en) 2004-07-28 2005-07-25 Substituted propenyl piperazine derivatives as novel inhibitors of histone deacetylase

Publications (3)

Publication Number Publication Date
BRPI0513891A BRPI0513891A (pt) 2008-05-20
BRPI0513891B1 BRPI0513891B1 (pt) 2020-09-29
BRPI0513891B8 true BRPI0513891B8 (pt) 2021-05-25

Family

ID=39294123

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513891A BRPI0513891B8 (pt) 2004-07-28 2005-07-25 derivados de propenil piperazina substituídos, seu uso como novos inibidores de histona deacetilase, composição farmacêutica, combinação e processo de preparação destes

Country Status (26)

Country Link
EP (1) EP1776358B1 (pt)
JP (1) JP5279268B2 (pt)
KR (1) KR101282833B1 (pt)
CN (1) CN1993356B (pt)
AR (1) AR050189A1 (pt)
AT (1) ATE432274T1 (pt)
AU (1) AU2005266311B2 (pt)
BR (1) BRPI0513891B8 (pt)
CA (1) CA2572971C (pt)
CY (1) CY1110358T1 (pt)
DE (1) DE602005014646D1 (pt)
DK (1) DK1776358T3 (pt)
EA (1) EA011932B1 (pt)
ES (1) ES2327253T3 (pt)
HK (1) HK1106236A1 (pt)
HR (1) HRP20090439T1 (pt)
IL (1) IL180961A0 (pt)
MX (1) MX2007001119A (pt)
MY (1) MY142831A (pt)
NO (1) NO20071117L (pt)
NZ (1) NZ552758A (pt)
PL (1) PL1776358T3 (pt)
PT (1) PT1776358E (pt)
SI (1) SI1776358T1 (pt)
TW (1) TWI394752B (pt)
WO (1) WO2006010749A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04007776A (es) 2002-03-13 2004-10-15 Janssen Pharmaceutica Nv Derivados de sulfonilamino como nuevos inhibidores de histona deacetilasa.
OA12790A (en) 2002-03-13 2006-07-10 Janssen Pharmaceutica Nv New inhibitors of histone deacetylase.
ATE398615T1 (de) 2002-03-13 2008-07-15 Janssen Pharmaceutica Nv Piperazinyl-, piperidinyl- und morpholinylderivate als neue inhibitoren von histon-deacetylase
WO2006010750A1 (en) 2004-07-28 2006-02-02 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
US8138198B2 (en) 2005-05-18 2012-03-20 Angibaud Patrick Rene Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
WO2007049262A1 (en) * 2005-10-27 2007-05-03 Berand Limited Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders
DK1981874T3 (da) 2006-01-19 2009-09-28 Janssen Pharmactuica N V Aminophenylderivater som nye inhibitorer af histondeacetylase
WO2007082874A1 (en) 2006-01-19 2007-07-26 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
JP5137849B2 (ja) 2006-01-19 2013-02-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼのインヒビターとしての置換インドリル−アルキル−アミノ−誘導体
CN101370789B (zh) * 2006-01-19 2012-05-30 詹森药业有限公司 作为组蛋白脱乙酰酶抑制剂的吡啶和嘧啶衍生物
EP1839656A1 (en) * 2006-03-31 2007-10-03 TopoTarget Germany AG Use of valproic acid for the topical treatment of mild to moderate acne vulgaris
CA2703718A1 (en) * 2007-11-02 2009-05-07 Tammy Mallais Inhibitors of histone deacetylase
CN101723896B (zh) * 2009-11-03 2012-10-31 山东大学 酪氨酸衍生物类组蛋白去乙酰化酶抑制剂及其应用
WO2012117421A1 (en) 2011-03-02 2012-09-07 Orchid Research Laboratories Ltd Histone deacetylase inhibitors
KR101419836B1 (ko) * 2012-05-10 2014-07-16 서울대학교산학협력단 Δ5-2-옥소피페라진 유도체를 포함하는 중간엽 줄기세포의 연골세포로의 분화 유도용 조성물
KR101586045B1 (ko) 2013-07-30 2016-01-15 충북대학교 산학협력단 신규 페닐티아졸 기반 히드록삼산 및 이를 유효성분으로 포함하는 항암용 조성물
KR102132078B1 (ko) 2018-09-20 2020-07-08 원광대학교산학협력단 방향족 화합물, 아민 및 친핵체를 이용한 3가지 성분 반응으로 1-에틸-4-페닐피페라진 유도체를 제조하는 방법
KR20230155310A (ko) 2022-05-03 2023-11-10 충북대학교 산학협력단 신규한 n-히드록시프로펜아미드 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
KR20230155311A (ko) 2022-05-03 2023-11-10 충북대학교 산학협력단 신규한 n-히드록시프로펜아미드 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH17194A (en) * 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
ATE398615T1 (de) * 2002-03-13 2008-07-15 Janssen Pharmaceutica Nv Piperazinyl-, piperidinyl- und morpholinylderivate als neue inhibitoren von histon-deacetylase
OA12790A (en) * 2002-03-13 2006-07-10 Janssen Pharmaceutica Nv New inhibitors of histone deacetylase.
JP4606027B2 (ja) * 2002-04-03 2011-01-05 トポターゲット ユーケー リミテッド Ｈｄａｃ阻害剤としてのピペラジン結合を有するカルバミン酸化合物

Also Published As

Publication number Publication date
HRP20090439T1 (hr) 2009-09-30
CN1993356A (zh) 2007-07-04
BRPI0513891B1 (pt) 2020-09-29
WO2006010749A2 (en) 2006-02-02
AU2005266311B2 (en) 2011-08-11
KR20070043978A (ko) 2007-04-26
SI1776358T1 (sl) 2009-10-31
AU2005266311A1 (en) 2006-02-02
EA200700143A1 (ru) 2007-06-29
KR101282833B1 (ko) 2013-07-08
CY1110358T1 (el) 2015-04-29
EP1776358B1 (en) 2009-05-27
DK1776358T3 (da) 2009-09-07
PT1776358E (pt) 2009-08-13
ATE432274T1 (de) 2009-06-15
JP2008508234A (ja) 2008-03-21
NO20071117L (no) 2007-02-27
CA2572971C (en) 2013-01-15
AR050189A1 (es) 2006-10-04
PL1776358T3 (pl) 2009-10-30
MY142831A (en) 2011-01-14
NZ552758A (en) 2009-08-28
CA2572971A1 (en) 2006-02-02
EA011932B1 (ru) 2009-06-30
EP1776358A2 (en) 2007-04-25
JP5279268B2 (ja) 2013-09-04
DE602005014646D1 (de) 2009-07-09
TW200616998A (en) 2006-06-01
CN1993356B (zh) 2010-10-27
BRPI0513891A (pt) 2008-05-20
HK1106236A1 (en) 2008-03-07
ES2327253T3 (es) 2009-10-27
MX2007001119A (es) 2007-03-15
WO2006010749A3 (en) 2006-06-08
TWI394752B (zh) 2013-05-01
IL180961A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
BRPI0513891B8 (pt) derivados de propenil piperazina substituídos, seu uso como novos inibidores de histona deacetilase, composição farmacêutica, combinação e processo de preparação destes
BRPI0512676B8 (pt) derivados de indolil alquil amina substituídos como inibidores de histona desacetilase, composição farmacêutica que os compreende, seus processos de preparação e uso
BR0307575A (pt) Derivados de sulfonila como inibidores de histona desacetilase
BR0307599A (pt) Derivados de sulfonilamino como inibidores de histona deacetilase
BR0308081A (pt) Inibidores de histona desacetilase
BR0307607A (pt) Derivados de carbonilamino como inibidores de histona desacetilase
BRPI0617167B8 (pt) sulfonilpirróis como inibidores de hdac's, seu uso, composição farmacêutica e combinação
BR112012011793A2 (pt) "acrilamidas heterocíclicas e seu uso como farmacêuticos"
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
BRPI0512938A (pt) derivados da quinazolinediona como inibidores parp
ATE432272T1 (de) Aminophenylderivate als neue inhibitoren von histondeacetylase
EA200401197A1 (ru) Пиперазинил-, пиперидинил- и морфолинилпроизводные как новые ингибиторы гистондеацетилазы
BRPI0515594A (pt) inibidores da interação entre mdm2 e p53
BRPI0512797A (pt) derivados de quinazolinona como inibidores de parp
BRPI0512902A (pt) derivados de ftalazina como inibidores de parp
AR055076A1 (es) Derivados de1,1-dioxido de 1,4-benzotiazepina,procedimiento para prepararlos,composiciones farmaceuticas que los contienen y usos en terapeutica.
BRPI0407811A (pt) composto derivados de pirazolopiridina, processo para a preparação dos mesmos, composição farmacêutica e respectivos uso
BRPI0821115A8 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
UA86066C2 (ru) Производные замещенного пропенилпиперазина как ингибиторы гистондеацетилазы
BRPI0512986A (pt) novos derivados de hidantoìna
BRPI0809542A8 (pt) Compostos derivados de indol tendo atividade de inibição de cpla2, composição farmacêutica, e métodos de produção dos referidos compostos
BRPI0616111B8 (pt) derivados de carboxamida, composição farmacêutica, uso dos mesmos e combinação
BRPI0714553B8 (pt) derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso
BRPI0517033A (pt) novos derivados de hidantoìna como inibidores de metaloproteinase
BRPI0508471A8 (pt) compostos de hidróxi-6-fenilfenantidinas substituídas por difluoroetóxi, composição farmacêutica e uso para a produção dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/07/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF